The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes/weight-loss med tirzepatide is over.

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — is over.

The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put a stop to companies making cheaper copies.